miscellaneous

systematic review meta-analysis network meta-analysis

Select angiotensin-receptor blockers All type of patient       angiotensin receptor blockerendopeptidase inhibitors ramiprilirbesartanlosartantelmisartancandesartanolmesartan vs placebo or controlvs angiotensin-converting enzyme inhibitorsvs beta-blockersvs calcium blockersvs calcium-channel blockersvs diuretics      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	All cause death (25)Cardiovascular death (22)stroke (fatal and non fatal) (21)myocardial infarction (fatal and non fatal) (18)Heart failure (15)cardiovascular events (13)Coronary event (9)Diabetes onset (8)Cancer (5)Revascularization (4)Adverse events leading to treatment discontinuation (4)Cough (4)angiodema (4)Hypotension (4)cardiac death (2)lung cancer (2)Non fatal stroke (2)Non fatal MI (2)cancer related death (1)cardiovascular death, MI, stroke (1)hypertension (1)Serious adverse event (1)macrovascular events (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	All cause death	Cardiovascular death
angiotensin-receptor blockers
not classified
Suzuki, 2008	ARBs	control			Risk of bias	negative
Ruilope, 2010	LCZ696	placebo			Low risk of bias	-
IDNT (irbesartan vs amlodipine), 2001	irbesartan	amlodipine			Low risk of bias	negative
VALUE, 2004      NCT	valsartan	amlodipine			Low risk of bias	suggesting
DETAIL, 2004	telmisartan	enalapril			Low risk of bias	negative
OSCAR, 2011      NCT	olmesartan 40 mg	olmesartan 20 mg plus a calcium-channel blocker			Risk of bias	negative
candesartan
Takahashi, 2006	candesartan	control			Exploratory	negative
E-COST, 2005	candesartan	conventional treatment			Risk of bias	suggesting
E-COST-R, 2005	candesartan	conventional treatment			Risk of bias	negative
HIJ-CREATE, 2009	candesartan	conventional treatment			Risk of bias	suggesting
SCOPE, 2003	candesartan	placebo			Low risk of bias	negative
TROPHY, 2006      NCT	candesartan	placebo			Low risk of bias	suggesting
CASE-J, 2008	candesartan	amlodipine			Risk of bias	suggesting
ALPINE, 2003	candesartan	hydrochlorothiazide			Low risk of bias	suggesting
irbesartan
IDNT (irbesartan vs pbo), 2001	irbesartan	placebo			Low risk of bias	negative
IRMA 2, 2001	irbesartan	placebo			Low risk of bias	negative
losartan
RENAAL, 2001	losartan	placebo			Low risk of bias	-
LIFE, 2002	losartan	atenolol			Low risk of bias	suggesting
olmesartan
ROADMAP, 2010        NCT	olmesartan	placebo			Low risk of bias	suggesting
ORIENT    NCT	olmesartan	placebo			Low risk of bias	negative
ramipril
ONTARGET (association vs ramipril), 2008    NCT	telmisartan + ramipril	ramipril			Low risk of bias	negative
ONTARGET (association vs telmisartan), 2008    NCT	telmisartan + ramipril	telmisartan			Low risk of bias	suggesting
telmisartan
TRANSCEND, 2008    NCT	telmisartan	placebo			Low risk of bias	suggesting
PROPHESS, 2008      NCT	telmisartan	placebo			Low risk of bias	negative
ONTARGET (telmisartan alone), 2008      NCT	telmisartan	ramipril			Low risk of bias	suggesting